Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Chemotherapy has been the standard for advanced pancreatic cancer, with limited patient benefit despite molecular advances.
• Mutant KRAS, a key driver, was historically undruggable, limiting targeted therapy options.
• The advent of KRAS inhibitors presents a potential paradigm shift for most pancreatic cancer patients.

Purpose of the Study:

• To review targeted therapies in pancreatic cancer.
• To discuss the clinical implications of KRAS-mutant and wild-type pancreatic cancer heterogeneity.
• To explore how biological insights can inform novel combination and sequential therapeutic strategies.

Main Methods:

• Review of clinical trial data, including the RASolute 302 trial.
• Analysis of preclinical and coclinical studies on KRAS inhibitor resistance.
• Discussion of genomic and transcriptomic heterogeneity in pancreatic cancer.

Main Results:

• RAS inhibition demonstrates clinically meaningful activity in metastatic pancreatic cancer, supporting regulatory approval.
• Intrinsic and acquired resistance mechanisms to KRAS inhibition have been identified.
• Pancreatic cancer treatment is transitioning towards precision oncology beyond rare molecular subgroups.

Conclusions:

• KRAS inhibitors represent a significant advancement, offering targeted treatment for a broader patient population.
• Understanding and overcoming resistance mechanisms is crucial for sustained therapeutic benefit.
• Future strategies must integrate genomic and transcriptomic insights to redefine precision oncology for pancreatic cancer.